CANDESARTAN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CANDESARTAN CILEXETIL

から入手可能:

SIVEM PHARMACEUTICALS ULC

ATCコード:

C09CA06

INN（国際名）:

CANDESARTAN

投薬量:

8MG

医薬品形態:

TABLET

構図:

CANDESARTAN CILEXETIL 8MG

投与経路:

ORAL

パッケージ内のユニット:

30/100/500

処方タイプ:

Prescription

治療領域:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

製品概要:

Active ingredient group (AIG) number: 0135220002; AHFS:

認証ステータス:

APPROVED

承認日:

2012-07-11

製品の特徴

_ _
_CANDESARTAN Product Monograph _
_Page 1 of 36_
PRODUCT MONOGRAPH
PR
CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg,16 mg and 32 mg
Manufacturer's Standard
Angiotensin II AT
1
Receptor Blocker
Sivem Pharmaceuticals ULC
Date of Preparation:
4705 Dobrin Street
July 11, 2012
Saint-Laurent, Quebec
Canada H4R 2P7
www.sivem.ca
Submission Control No.: 264183
Date of
Revision:
June 20, 2022
_ _
_CANDESARTAN Product Monograph _
_Page 2 of 36_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................................
8
DRUG
INTERACTIONS
........................................................................................................................................
12
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
15
OVERDOSAGE
......................................................................................................................................................
17
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
17
STORAGE
AND
STABILITY
.......................................................................